Company: RPID
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0001380106-25-000089
Chunk: 50

Company: RAPID MICRO BIOSYSTEMS, INC.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 50
---
 be automatically increase on January 1 of each calendar year beginning in 2022 and ending in and including 2031, by an amount equal to the lesser of (A) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares as is determined by our board of directors, provided that no more than 6,300,000 shares of our Class A common stock may be issued under the ESPP. On January 1, 2025, the number of shares available for issuance under the ESPP increased automatically by 377,292 shares pursuant to this provision. This increase is not reflected in the table above. (5) As of December 31, 2024, there were 5,073,051 shares available for grant under the 2021 Plan and 956,940 shares available for issuance under the ESPP. (6) Includes securities issuable upon rights that were granted pursuant to our 2023 Inducement Plan (the "2023 Plan"). (7) Includes (i) 237,083 shares of Class A common stock issuable upon the exercise of outstanding options, (ii) 75,000 shares of Class A common stock issuable upon vesting of restricted stock units. (8) Effective February 24, 2025, the number of shares available for issuance under the 2023 Plan increased by 476,000 shares pursuant to the approval of the 2023 Plan Amendment. This increase is not reflected in the table above. 33

#### TABLE OF CONTENTS

# PART 5 – AUDIT COMMITTEE MATTERS

### REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS
Our Audit Committee was established in 2021 at the time of our initial public offering. During 2024, the Audit Committee was comprised of Melinda Litherland, Richard Kollender and Inese Lowenstein. The most recently amended Audit Committee Charter is available in the Corporate Governance section of our web site, investors.rapidmicrobio.com.

The Audit Committee oversees the accounting and financial reporting processes of Rapid Micro Biosystems and the audits of the consolidated financial statements of Rapid Micro Biosystems on behalf of the Board of Directors. Our management is responsible for our internal controls and our financial reporting processes. Our independent registered public accounting firm is responsible for performing an independent audit of our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America.

The Audit Committee has reviewed Rapid